1997
Low-grade gliomas: Introduction and overview
Piepmeier J, Christopher S. Low-grade gliomas: Introduction and overview. Journal Of Neuro-Oncology 1997, 34: 01-03. PMID: 9210048, DOI: 10.1023/a:1005798901779.Peer-Reviewed Original Research
1996
Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas.
Piepmeier J, Susan Christopher R, Spencer D, Byrne T, Kim J, Knisel J, Lacy J, Tsukerman L, Makuch R. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996, 38: 872-8; discussion 878-9. PMID: 8727811, DOI: 10.1097/00006123-199605000-00002.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGross total resectionChronic epilepsySupratentorial low-grade astrocytomasNatural historyGross total tumor resectionImmediate postoperative radiotherapyExtent of surgerySurvival of patientsTen-year survivalPopulation of patientsUse of radiotherapyRisk of recurrenceHigh-grade lesionsLength of survivalMore malignant tumorsTypes of symptomsAggressive surgeryPostoperative radiotherapyPreoperative symptomsConsecutive patientsBetter prognosisTumor recurrenceTumor resectionMalignant tumorsA phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
Halperin E, Herndon J, Schold S, Brown M, Vick N, Cairncross J, Macdonald D, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel G, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. International Journal Of Radiation Oncology • Biology • Physics 1996, 34: 793-802. PMID: 8598355, DOI: 10.1016/0360-3016(95)02025-x.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyKarnofsky performance statusMedian survivalSurvival benefitERT groupAnaplastic gliomasBeam radiotherapyMitomycin CVs. 11.4 monthsProportion of patientsSignificant survival benefitPossible survival benefitTreatment of adultsYears of ageBCNU groupPerformance statusProspective trialHistologic diagnosisMalignant gliomasMito groupStereotactic biopsyPatientsGreater riskFourth weekThird day
1992
Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study.
Bracken M, Shepard M, Collins W, Holford T, Baskin D, Eisenberg H, Flamm E, Leo-Summers L, Maroon J, Marshall L, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H, Young W. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. Journal Of Neurosurgery 1992, 76: 23-31. PMID: 1727165, DOI: 10.3171/jns.1992.76.1.0023.Peer-Reviewed Original ResearchConceptsHours of injuryAcute spinal cord injurySpinal cord injuryNaloxone treatmentCord injuryMotor functionSecond National Acute Spinal Cord Injury StudyNational Acute Spinal Cord Injury StudyAcute Spinal Cord Injury StudySpinal Cord Injury StudyAcute spinal cord traumaPreservation of motorTrial of methylprednisoloneSpinal cord traumaTotal sensoryPlacebo groupCord traumaNeurological functionStudy doseEmergency roomMethylprednisoloneInjury studiesMortality ratePatientsSensory function